NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Musculoskeletal > Oxford leads part of major COVID-19 drugs trial

Oxford leads part of major COVID-19 drugs trial

10 June 2020 · Listed under COVID-19, Musculoskeletal

As part of a new UK trial researchers at the University of Oxford will investigate whether administering the anti-inflammatory drug infliximab to patients with COVID-19 can prevent progression to respiratory failure or death.

The multi-arm, multi-stage CATALYST Trial, is being led by the University of Birmingham in partnership with University Hospitals Birmingham and the Birmingham NIHR Biomedical Research Centre (BRC). The trial is a collaboration with the NIHR Oxford BRC and University College London NIHR BRC.

In some patients, COVID-19 can progress to severe respiratory failure requiring admission to an intensive care unit and mechanical ventilation of the lungs. This does not occur immediately but seems to progress over 7-10 days after first developing symptoms of the disease. 

The overall aim of the CATALYST Trial is to guide the selection of new drug interventions for large phase III trials in hospitalised patients with COVID-19 infection.

It is hoped that by using drugs that target the most serious symptoms of the virus, the severity of the disease could be mitigated, leading to a reduction in the number of patients needing to be admitted to intensive care and ultimately, a reduction in virus-related deaths.

The Oxford arm of the study, led by Professor Duncan Richards of the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, and Dr Matt Rowland of the Nuffield Department of Clinical Neurosciences, is funded by UK Research and Innovation with support from the arthritis therapy acceleration programme (A-TAP), University of Oxford Medical Sciences Division COVID fund, and Helena Charitable Foundation.

Infliximab (CT-P13), produced by Slough based Celltrion Healthcare UK, is an anti-tumour necrosis factor (TNF) therapy that is designed to attach to a protein involved in inflammation. It is currently used as a treatment for conditions including rheumatoid arthritis and inflammatory bowel syndrome under the trade name Remsima®.

The Oxford researchers will explore exactly how this drug works to reduce inflammation caused by COVID-19 by taking blood and other samples from critically unwell patients.

The effect of the drug will be measured by the amount of oxygen required by patients, as well as assessment of other severity indicators of the disease, such as organ failure. Drugs in the CATALYST trial that show efficacy in these measures will be recommended for further testing within large ongoing national trials.

“We hope that by using a treatment that is already used to treat inflammation in other autoimmune conditions we may be able to manage inflammation associated with COVID-19 early,” said Sir Marc Feldmann, Professor of Immunology at the University of Oxford.

“The study will recruit across Birmingham and Oxford initially, but we expect that other centres will join the study soon. We are collaborating closely with Birmingham on the plans for analysis of complex biomarkers,” Prof Richards, the Oxford BRC’s Co-theme Lead for Musculoskeletal.

“We believe these will provide important mechanistic insights into the drugs in the study and are an important aspect of the clinical and scientific value of this study.”

In another arm of the CATALYST trial, the Oxford-based biopharmaceutical company Izana Bioscience will provide Namilumab (IZN-101),  a fully human monoclonal antibody already in late-stage trials to treat rheumatoid arthritis and an inflammatory disease called ankylosing spondylitis.

It targets a ‘cytokine’ called GM-CSF (granulocyte-macrophage colony stimulating factor), which is naturally secreted by immune cells in the body but, in uncontrolled levels, is believed to be a key driver of the excessive and dangerous lung inflammation seen in COVID-19 patients.

← First patient recruited for key drug treatment trial
Study explores effects of COVID-19 on sleep →

News

  • Study highlights ongoing COVID-19 risk in some cancer patients despite vaccination 24 May 2022
  • BRC study outlines researchers training needs and barriers 20 May 2022
  • Three new Blood and Transplant Research Units created in Oxford 18 May 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre